Qureight lands £15m Series B led by Molten Ventures to bring AI imaging to clinical trials for lung and heart disease

Qureight is an end-to-end imaging company that provides enterprise-grade imaging and precision endpoints for clinical trials, with a focus on lung and heart disease. Deep learning models built on 3D chest imaging quantify structural changes that indicate disease progression, giving biopharma partners measurable endpoints during trials.